Amphivena Therapeutics, Inc. Overview
Pro stress-test →Amphivena Therapeutics, Inc. is a privately held, clinical-stage, oncology company based in South San Francisco, CA with a mission to restore anti-cancer immunity in patients and to take cancer treatment beyond the limits of immunotherapy. The company's proprietary Amphivena ReSTORE platform of bivalent T-cell engagers is designed to selectively relieve immune suppression and drive T-cell activation/polarization in patients.
Strategic Profile
Pro stress-test →The company's lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy, and in parallel, drives improved T cell effector function. The company is advancing AMV564 through Phase 1 clinical development across multiple solid tumor indications and hematologic malignancies.
Competitive Landscape
Pro stress-test →Amphivena competes in the immuno-oncology and T-cell engager space against established players developing checkpoint inhibitors and bispecific T-cell engaging antibodies. Direct competitors include Roche/Genentech (BiTE platform), Juno Therapeutics/Bristol Myers Squibb (CAR-T), and emerging bispecific companies like Thirty Thirty Therapeutics and Alnylam. Amphivena's differentiation lies in its MDSC-targeting, bivalent T-cell engager approach combined with subcutaneous dosing, positioning it as an adjunct to rather than replacement for checkpoint inhibitors.
Industry Context
Amphivena Therapeutics, Inc. operates in Immuno-oncology T-cell engager therapeutics.
Key facts
Founded: 2012 · Headquarters: South San Francisco, US · Employees: 17